Michael Castro, MD - Caris MI и …...To order Caris Molecular Intelligence Services or to speak...
2
EDUCATION 1986 M.D. Columbia – College of Physicians and Surgeons 1982 PreMed Harvard University and Brandeis University 1979 B.A. Brandeis University POSTDOCTORAL TRAINING 1994 Post Graduate in Biochemotherapy of Renal Cell Carcinoma and Melanoma MD Anderson Cancer Center, Houston, Texas 1989-1991 Fellow, Neoplastic Diseases Mt. Sinai Medical Center, New York, New York 1986-1989 Resident, Internal Medicine St. Lukes – Roosevelt Hospital, New York, New York CURRENT PRACTICE 2012 - Present Personalized Cancer Medicine, PLLC Honolulu, Hawaii CERTIFICATION American Board of Internal Medicine American Board of Medical Oncology NIH Certification of Human Subjects Research ACADEMIC APPOINTMENTS 2001 - Present Clinical Associate Professor of Medicine University of Vermont, Burlington, Vermont Michael Castro, MD Senior Medical Director
Transcript of Michael Castro, MD - Caris MI и …...To order Caris Molecular Intelligence Services or to speak...
E D U C AT I O N
1986 M.D. Columbia – College of Physicians and Surgeons
1982 PreMed Harvard University and Brandeis University
1979 B.A. Brandeis University
P O S T D O C T O R A L T R A I N I N G
1994 Post Graduate in Biochemotherapy of Renal Cell Carcinoma and Melanoma MD Anderson Cancer Center, Houston, Texas
1989-1991 Fellow, Neoplastic Diseases Mt. Sinai Medical Center, New York, New York
1986-1989 Resident, Internal Medicine St. Lukes – Roosevelt Hospital, New York, New York
C U R R E N T P R A C T I C E
2012 - Present Personalized Cancer Medicine, PLLC Honolulu, Hawaii
C E R T I F I C AT I O N
American Board of Internal Medicine
American Board of Medical Oncology
NIH Certification of Human Subjects Research
A C A D E M I C A P P O I N T M E N T S
2001 - Present Clinical Associate Professor of Medicine University of Vermont, Burlington, Vermont
Michael Castro, MD Senior Medical Director
© 2013 Caris Life Sciences and affiliates. All rights reserved. TN0103 1.13
Pharmacokinteics Of Bsi-201, A Poly (Adp-Ribose) Polymerase-1 (Parp1) Inhibitor In Cerebrospinal Fluid Of A Breast Cancer Patient With Carcinomatous Meningitis. M Castro, L Li, Te Stallings. Proc Am Soc Clin Oncol 2010, Abstract 48374
Peripheral Sensory Neuropathy - Fighting Cold With Cold. Castro Mp Lancet Oncol 2008 9:415-6
Pharmacogenetics In The Clinic: The New Questions About Tamoxifen. Castro Mp. J Oncol Prac 2006 2:100
Resisting A Fundamentalist Philosophy. M Castro J Clin Oncol 2005 23:3645-46
Bisphosphonate-Induced Osteosclerosis In A Breast Cancer Patient. Castro Mp, Novak S, Whyte Mp. J Bone & Mineral Res 2005
Pharmacogenetic Correlates Of Benefit From Gemcitabine And Platinum In Patients With Advanced Bladder Cancer. M Castro, A Neumann, M Konichexky, K Dannenberg, S Stemmer Proc Am Soc Clin Oncol 2004 Abstract 3203
Thymidine Rescue: An Antidote For Pemetrexed Related Toxicity In The Setting Of Acute Renal Failure, M. Castro, J Clin Oncol 2003, 21:4066
Targeted Therapy. M. Castro In Heme-Onc Secrets Ed. M. Wood. University Of Vermont Press 2003.
Timing Is Everything Or Could Be. M. Castro J Clin Oncol 21: 755, 2003.
The Simpleton’s Error In Drug Development. M. Castro. J Clin Oncol 2002 20: 4606-7.
Eniluracil’s Need For A Targeted Approach: A Lesson In Drug Development. M Castro. J Clin Oncol 2002 20: 3750.
Ex-Vivo Apoptotic Assay (Eva)-Directed Use Of Gemcitabine As Salvage Therapy In Colorectal Carcinoma: Case Report. M Castro. Lilly Oncology Investigators Meeting. April 4, 2002
Successful Use Of Anti-Cd20 Monoclonal Antibody, Rituxan, In Patients With Non-Hodgkin’s Lymphoma And Renal Insufficiency. Castro Mp, Vanauken J, Sponzo Rw. Proc. Am Soc Clin Oncol 2001, 20:3325.
Cerebrospinal Fluid Gastrin-Releasing Peptide In The Diagnosis Of Leptomeningeal Metastases In Small Cell Carcinoma. Mp Castro, S Qualman, T Odorisio, Cancer 2001, 91:2122-2126.
Cyclophosphamide, 5-Fluorouracil And Prednisone (Cfp) In Hormone Refractory Prostate Cancer. Mp Castro, J Vanauken, N Oberhelman, Rw Sponzo. Proc Am Soc Clin Oncol. 2000, 19:1435,.
The Impact Of Risk Stratification Of Mammographic Interpretation. R Sponzo, T Ashikaga, C Howland, P Cisek, Mp Castro. Proc Am Soc Clin Oncol 2000, 19:335.
Have The Recently Completed Phase Iii Trials Significantly Impacted Adjuvant Treatment Choices For Stage Ii Breast Carcinoma? Middleman E, Castro Mp, Gradishar W. Semin Oncol, 1999, 26(4): Xvi, Xvii-Xx,.
Acute Tumor Lysis Syndrome Associated With Concurrent Biochemotherapy Of Metastatic Melanoma: A Case Report And Review Of The Literature. Castro Mp, S Legha, J Van Auken, P Cisek, Rw Sponzo. Cancer 1999 85(5): 1055-9.
Efficacy Of Gemcitabine In The Treatment Of Patients With Gallbladder Carcinoma; A Case Report. M. Castro, Cancer 1998, 82(4): 639-41.
Clinicopathologic Correlations With Mucin Carbohydrate Antigen Expression In Breast Cancer. M. Castro, J. Strauchen, J. Mandeli, R. Perles, J. Morrison, S. Itzkowitz. Proc Am Soc Clin Oncol, 1991 10:200.
S E L E C T P U B L I C AT I O N S
P R O F E S S I O N A L S O C I E T I E S
American Society of Clinical Oncology American Medical Association
To order Caris Molecular Intelligence Services or to speak with a Caris Life Sciences’ representative, call
( 8 8 8 ) 9 7 9 - 8 6 6 9 or visit us online at www.CarisMolecularIntelligence.com.
